Gain Therapeutics (NASDAQ:GANX) Given “Buy” Rating at Chardan Capital

Chardan Capital reaffirmed their buy rating on shares of Gain Therapeutics (NASDAQ:GANX) in a research note released on Friday morning,Benzinga reports. Chardan Capital currently has a $6.00 target price on the stock.

GANX has been the topic of several other research reports. Roth Mkm reissued a “buy” rating and set a $7.00 price target on shares of Gain Therapeutics in a research report on Tuesday, December 24th. Scotiabank began coverage on shares of Gain Therapeutics in a report on Friday, March 7th. They issued a “sector outperform” rating and a $12.00 target price on the stock. HC Wainwright restated a “buy” rating and set a $8.00 price target on shares of Gain Therapeutics in a report on Monday, March 17th. Finally, Roth Capital upgraded Gain Therapeutics to a “strong-buy” rating in a report on Thursday, December 5th. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $8.20.

Gain Therapeutics Stock Down 8.7 %

GANX stock opened at $1.89 on Friday. The company has a current ratio of 2.99, a quick ratio of 2.99 and a debt-to-equity ratio of 0.04. The firm has a 50-day moving average of $2.22 and a two-hundred day moving average of $2.06. Gain Therapeutics has a 12 month low of $0.89 and a 12 month high of $4.04. The company has a market cap of $50.13 million, a price-to-earnings ratio of -1.72 and a beta of 0.14.

Gain Therapeutics (NASDAQ:GANX) last posted its quarterly earnings results on Thursday, March 27th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.07. As a group, analysts forecast that Gain Therapeutics will post -1 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Gain Therapeutics

Large investors have recently made changes to their positions in the stock. Marshall Wace LLP purchased a new stake in Gain Therapeutics in the fourth quarter valued at approximately $198,000. Geode Capital Management LLC grew its stake in shares of Gain Therapeutics by 48.0% in the third quarter. Geode Capital Management LLC now owns 271,972 shares of the company’s stock valued at $484,000 after buying an additional 88,236 shares in the last quarter. Jones Financial Companies Lllp raised its holdings in shares of Gain Therapeutics by 83.6% in the 4th quarter. Jones Financial Companies Lllp now owns 98,250 shares of the company’s stock valued at $212,000 after buying an additional 44,750 shares during the period. Northern Trust Corp lifted its stake in Gain Therapeutics by 88.2% during the 4th quarter. Northern Trust Corp now owns 84,586 shares of the company’s stock worth $183,000 after acquiring an additional 39,642 shares in the last quarter. Finally, Bridgeway Capital Management LLC acquired a new position in Gain Therapeutics in the 4th quarter valued at about $65,000. 11.97% of the stock is currently owned by institutional investors and hedge funds.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.